Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 29;6(11):e103. doi: 10.1038/emi.2017.91

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Protective efficacy of inactivated FAdV-4 vaccine against the FAdV-4 and FAdV-8a virulent challenge. (A) The mean lesions scores of vaccinated group (a and b) and unvaccinated group (c and d) challenged with the FAdV-4 strain. There were no lesions in the liver, heart and kidney in groups a and b, whereas birds in groups c and d showed severe lesions. (B) The viral detection rate in cloacal swabs of the vaccinated group (a and b) and unvaccinated group (c and d) challenged with the FAdV-4 strain. The viral detection rate in cloacal swabs of groups a and b were highly significantly different compared with groups c and d. (C) The mean lesion scores of the vaccinated groups (e and f) and unvaccinated groups (g and h) challenged with FAdV-8a strain. The vaccine significantly reduced the lesions caused by FAdV-8a. (D) The viral detection rate in cloacal swabs of vaccinated (e and f) and unvaccinated groups (g and h) challenged with FAdV-8a strain. The vaccine significantly reduced the rate of viral detection in cloacal swabs challenged with the FAdV-8a strain. *P<0.001 was considered very highly significant.